Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Table 1

Baseline characteristics in the whole study population and the subset with tissue specimen available.

	RAKET		Satellite
	Main study	Examined group	Main study	Examined group
𝑛 =	151	35	71	34
Median age	62 (43–78)	61 (49–78)	62 (42–81)	62 (43–76)
Gender F/M	48/52%	46/54%	51/49%	53/47%
PS 0/1	55/45%	40/60%	62/38%	65/35%
Stage IIIA/IIIB	34/66%	29/71%	37/62%	24/76%
Weight loss > 5%	17%	26%	37%	32%
FEV1	2.1 (0.8–4.5)	2.2 (0.9–4.3)	2.2 (1.1–3.7)	2.1 (1.1–3.7)
Histology:
Adenocarcinoma	48%	63%	49%	44%
SCC	32%	26%	39%	44%
NSCLC NOS	20%	11%	12%	12%